2025-01-01 2025-12-31 2025-12-31 false 08341685 MSA Eyecare Limited 86220Specialists medical practice activities iso4217:GBP xbrli:pure 083416852025-01-01 083416852025-12-31 083416852025-01-01 2025-12-31 08341685bus:SmallEntities2025-01-01 2025-12-31 08341685bus:AuditExempt-NoAccountantsReport2025-01-01 2025-12-31 08341685bus:FullAccounts2025-01-01 2025-12-31 08341685core:WithinOneYear2025-12-31 08341685core:AfterOneYear2025-12-31 08341685core:WithinOneYear2025-01-01 2025-12-31 08341685core:AfterOneYear2025-01-01 2025-12-31 08341685core:CurrentFinancialInstruments2025-12-31 08341685core:Non-currentFinancialInstruments2025-12-31 08341685core:CurrentFinancialInstruments2025-01-01 2025-12-31 08341685core:Non-currentFinancialInstruments2025-01-01 2025-12-31 08341685core:LandBuildings2025-01-01 2025-12-31 08341685core:FurnitureFittings2025-01-01 2025-12-31 08341685core:OfficeEquipment2025-01-01 2025-12-31 08341685core:Vehicles2025-01-01 2025-12-31 08341685core:PlantMachinery2025-01-01 2025-12-31 08341685core:OtherPropertyPlantEquipment2025-01-01 2025-12-31 08341685core:LandBuildings2025-12-31 08341685core:PlantMachinery2025-12-31 08341685core:Vehicles2025-12-31 08341685core:FurnitureFittings2025-12-31 08341685core:OfficeEquipment2025-12-31 08341685core:OtherPropertyPlantEquipment2025-12-31 08341685core:Right-of-useAssets2025-01-01 2025-12-31 08341685core:Right-of-useAssets2025-12-31 08341685core:Goodwill2025-01-01 2025-12-31 08341685core:PatentsTrademarksLicencesConcessionsSimilar2025-01-01 2025-12-31 08341685core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-01-01 2025-12-31 08341685core:OtherResidualIntangibleAssets2025-01-01 2025-12-31 08341685core:Goodwill2025-12-31 08341685core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-12-31 08341685core:PatentsTrademarksLicencesConcessionsSimilar2025-12-31 08341685core:OtherResidualIntangibleAssets2025-12-31 08341685dpl:CostSales2025-01-01 2025-12-31 08341685dpl:AdministrativeExpenses2025-01-01 2025-12-31 08341685dpl:DistributionCosts2025-01-01 2025-12-3108341685core:ShareCapital2025-12-31 08341685core:SharePremium2025-12-31 08341685core:RevaluationReserve2025-12-31 08341685core:OtherReservesSubtotal2025-12-31 08341685core:ShareCapitalPreferenceShares2025-12-31 08341685core:CapitalRedemptionReserve2025-12-31 08341685core:OtherCapitalReserve2025-12-31 08341685core:RetainedEarningsAccumulatedLosses2025-12-3108341685core:ShareCapital2025-01-01 2025-12-31 08341685core:SharePremium2025-01-01 2025-12-31 08341685core:RevaluationReserve2025-01-01 2025-12-31 08341685core:OtherReservesSubtotal2025-01-01 2025-12-31 08341685core:RetainedEarningsAccumulatedLosses2025-01-01 2025-12-310834168512025-01-01 2025-12-31 0834168522025-01-01 2025-12-3108341685core:ShareCapital12025-01-01 2025-12-31 08341685core:ShareCapital22025-01-01 2025-12-3108341685core:SharePremium12025-01-01 2025-12-31 08341685core:SharePremium22025-01-01 2025-12-3108341685core:RevaluationReserve12025-01-01 2025-12-31 08341685core:RevaluationReserve22025-01-01 2025-12-3108341685core:RetainedEarningsAccumulatedLosses12025-01-01 2025-12-31 08341685core:RetainedEarningsAccumulatedLosses22025-01-01 2025-12-310834168512025-01-01 2025-12-3108341685core:Non-currentFinancialInstrumentscore:CostValuation2025-01-01 08341685core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-12-31 08341685core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-12-3108341685core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-12-31 08341685core:Non-currentFinancialInstrumentscore:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments2025-12-31 08341685core:Non-currentFinancialInstrumentscore:CostValuation2025-12-3108341685core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2025-01-01 08341685core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-12-31 08341685core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-12-31 08341685core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-12-31 08341685core:Non-currentFinancialInstrumentscore:FurtherSpecificIncreaseDecreaseInProvisionsForImpairmentInvestments1ComponentCorrespondingTotal2025-12-31 08341685core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-12-31 08341685core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2025-12-3108341685core:Non-currentFinancialInstruments2025-12-31 08341685core:Non-currentFinancialInstruments2024-12-31083416852024-01-01 083416852024-12-31 083416852024-01-01 2024-12-31 08341685core:WithinOneYear2024-12-31 08341685core:AfterOneYear2024-12-31 08341685core:CurrentFinancialInstruments2024-12-31 08341685core:Non-currentFinancialInstruments2024-12-31 08341685core:LandBuildings2024-12-31 08341685core:PlantMachinery2024-12-31 08341685core:Vehicles2024-12-31 08341685core:FurnitureFittings2024-12-31 08341685core:OfficeEquipment2024-12-31 08341685core:OtherPropertyPlantEquipment2024-12-31 08341685core:Right-of-useAssets2024-12-31 08341685core:Goodwill2024-12-31 08341685core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-12-31 08341685core:PatentsTrademarksLicencesConcessionsSimilar2024-12-31 08341685core:OtherResidualIntangibleAssets2024-12-31 08341685dpl:AdministrativeExpenses2024-01-01 2024-12-3108341685core:ShareCapital2024-12-31 08341685core:SharePremium2024-12-31 08341685core:RevaluationReserve2024-12-31 08341685core:OtherReservesSubtotal2024-12-31 08341685core:ShareCapitalPreferenceShares2024-12-31 08341685core:CapitalRedemptionReserve2024-12-31 08341685core:OtherCapitalReserve2024-12-31 08341685core:RetainedEarningsAccumulatedLosses2024-12-3108341685core:RetainedEarningsAccumulatedLosses2024-01-01 08341685core:ShareCapital2024-01-01 08341685core:SharePremium2024-01-01 08341685core:RevaluationReserve2024-01-01 08341685core:ShareCapital2024-01-01 2024-12-31 08341685core:SharePremium2024-01-01 2024-12-31 08341685core:RevaluationReserve2024-01-01 2024-12-31 08341685core:OtherReservesSubtotal2024-01-01 2024-12-31 08341685core:RetainedEarningsAccumulatedLosses2024-01-01 2024-12-310834168512024-01-01 2024-12-31 0834168522024-01-01 2024-12-3108341685core:ShareCapital12024-01-01 2024-12-31 08341685core:ShareCapital22024-01-01 2024-12-3108341685core:SharePremium12024-01-01 2024-12-31 08341685core:SharePremium22024-01-01 2024-12-3108341685core:RevaluationReserve12024-01-01 2024-12-31 08341685core:RevaluationReserve22024-01-01 2024-12-3108341685core:RetainedEarningsAccumulatedLosses12024-01-01 2024-12-31 08341685core:RetainedEarningsAccumulatedLosses22024-01-01 2024-12-3108341685bus:Director12025-01-01 2025-12-3108341685bus:Director22025-01-01 2025-12-3108341685bus:PrivateLimitedCompanyLtd2025-01-01 2025-12-31
MSA Eyecare Limited
Unaudited Financial Statements
for the year ended 31 December 2025
Company registration number 08341685
(England and Wales)

Company Information

For the year ended 31 December 2025
Directors Saanan, Shazia
Umeed, Saanan, Dr

Company secretary Saanan, Shazia

Registered office Broadway House
Broadway
Cardiff
CF24 1PU

Registered number 08341685

Accountant SNK Associates
Broadway House
9-10 Upper Clifton Street
Cardiff
Wales
CF24 1PU

Statement of Financial Position

As at 31 December 2025
2025
2024
£
£
£
£
Fixed assets
Tangible assets
10,853
1,395
10,853
1,395
Current assets
Cash at bank and in hand
180,028
148,062
180,028
148,062
Creditors
Amounts falling due within one year
(24,159)
(13,140)
(24,159)
(13,140)
Net current assets (liabilities)
155,869
134,922
Total assets less current liabilities
166,722
136,317
Net assets (liabilities)
166,722
136,317
Capital and reserves
Called up share capital
2
2
Profit and loss account
166,720
136,315
Total equity
166,722
136,317

The company is a private company limited by shares and registered in England and Wales. It was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
The financial statements have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company's profit and loss account under section 444 (5A) of the Companies Act 2006.

The financial statements were approved and authorised for issue by the Board of Directors on 24 September 2026 and are signed on its behalf by:

Saanan, Shazia
Saanan, Shazia
Director
Umeed, Saanan, Dr
Umeed, Saanan, Dr
Director

Company registration number 08341685

Notes to the Financial Statements

For the year ended 31 December 2025

1. Statutory information

The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The financial statements are presented in sterling and this is the functional currency of the company.

2. Accounting policies

2.1. Basis of preparation

The financial statements have been prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

The financial statements have been prepared under the historical cost convention in accordance with the Companies Act 2006.

3. Employees

The average number of employees during the year was 0 (2024: 0).